Across TCGA pan-cancer cohorts, CRK Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CRK data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CRK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRK expression acts as an unfavorable survival marker.
CESC, PRAD, and SKCM are the cancer types where CRK Mutation most reproducibly stratifies survival.